Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 31, 2025International Journal of Clinical PharmacyOpen Access

Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool

View Full Paper
Ask AI
Bookmark
Share

Authors

RARogério Caixinha AlgarvioJCJaime ConceiçãoPRPedro Pereira Rodrigues

Discussion

Loading...

Member takes

Overview

Narrative review highlights artificial intelligence’s impact on drug safety and efficiency in pharmacovigilance, suggesting significant improvements in adverse drug reaction management.

Key Points

  • AI enhances pharmacovigilance by streamlining signal detection and automating adverse drug reactions reporting.
  • The use of a Bayesian network at a pharmacovigilance center reduced causality assessment processing times from days to hours.
  • Data mining techniques employed by AI expedite safety signal identification, improving drug safety evaluations.
  • Despite promising improvements, practical AI application in pharmacovigilance is limited by data quality and regulatory challenges.

Cite This Study

Algarvio et al. (2025) studied this question.

synapsesocial.com/papers/689a094be6551bb0af8cf416https://doi.org/10.1007/s11096-025-01975-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration2025
  2. 2Artificial intelligence in pharmacovigilance signal management: a review of tools, implementations, research, and regulatory landscape.2025
  3. 3In situ development of an artificial intelligence (AI) model for early detection of adverse drug reactions (ADRs) to ensure drug safety2025
  4. 4Enhancing the Patient Safety by using the Explainable Artificial Intelligence in Pharmacovigilance2025
  5. 5Beyond black boxes: using explainable causal artificial intelligence to separate signal from noise in pharmacovigilance2025